Renowned Clinicians. Virology and Oncology Thought Leaders.
Our Scientific and Clinical Advisors bring a wide range of expertise to guide our growing clinical program, as well as to support the foundation of our scientific discovery efforts.
Center Director and Professor, Biodesign Center for Immunotherapy, Vaccines and Virotherapy
Stanley Frankel, MD
Dr. Frankel brings a wealth of experience and knowledge in hematology, cell therapy and immuno-oncology accumulated at Bristol-Myers Squibb (BMS) where he was Senior Vice President, Cellular Therapy Development, and responsible for late development portfolio of cellular therapy assets including Breyanzi® (lisocabtagene maraleucel) and Abecma® (idecabtagene vicleucel). Prior to this experience, Dr. Frankel was Corporate Vice President, Head, Immuno-Oncology & Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence at Celgene and served on joint steering and/or joint development committees for alliances with JW Therapeutics, Jounce Therapeutics, AstraZeneca/MedImmune, Juno Therapeutics, and BeiGene.
Jose Iglesias, MD
Jose Iglesias, M.D. brings decades of expertise in clinical development strategy, clinical trial design, biomarker-guided pharmacodynamics, proof of principle and proof of concept studies, drug approval strategies, studies to support commercialization, academic research collaborations and liaisons with worldwide centers of excellence and oncology cooperative groups. Dr. Iglesias served as Chief Medical Officer at Senti Biosciences, Biothera Pharmaceuticals, Bionomics Ltd., Abraxis Bioscience Inc. and as Vice President, Clinical Development at Celgene.
Michael Morse, MD
Professor of Medicine, Professor in the Department of Surgery, Member of the Duke Cancer Institute
Kunle Odunsi, MD, PhD
Deputy Director, Chair of the Department of Gynecologic Oncology and Executive Director, Center for Immunotherapy, Co-Leader, Tumor Immunology and Immunotherapy Program Roswell Park Cancer Institute
Dr. Adekunle "Kunle" Odunsi is Deputy Director, Chair of the Department of Gynecologic Oncology, Executive Director of the Center for Immunotherapy, and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Comprehensive Cancer Center. He provides operational oversight for the scientific, clinical research and educational missions of Roswell Park, and monitors all research-related initiatives, steering development of programs and policies designed to transfer scientific discoveries to clinical settings.
He joined RoswelI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology, Department of Surgical Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991.
Dr. Odunsi completed a research fellowship in Molecular Oncology and earned his Doctor of Philosophy at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK. Subsequently, he completed residency training in Obstetrics & Gynecology at the Yale University School of Medicine, New Haven, CT, and clinical fellowship in Gynecologic Oncology at Roswell Park. He is a Fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom. He is also a Fellow of the American College of Obstetricians and Gynecologists. In 2018, Dr. Odunsi was elected into the National Academy of Medicine, a distinguished lifetime designation that is considered one of the highest honors in health and medicine.
Dr. Odunsi is licensed by New York State and certified in Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. He is also board certified in the subspecialty of Gynecologic Oncology.
Dr. Odunsi’s research interests include the molecular characterization of tumor antigens in ovarian cancer and their application to the development of vaccine therapies for the disease.
Dr. Odunsi has authored or co-authored more than 300 journal publications and book chapters. He is Associate Editor for BMC Cancer. He also is an Ad Hoc Reviewer for the American Journal of Obstetrics and Gynecology, BLOOD, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Cancer Letters, Cancer Research, Clinical Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, International Journal of Cancer, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings, Molecular Cancer Therapeutics, Oncogene, Oncology PLoS ONE and the Proceedings of the National Academy of Sciences, U.S.A.